stockrowGilead Sciences, Inc. (GILD) vs Merck & Co., Inc. (MRK)
- Gilead Sciences, Inc. GILD 166.96 −0.36%
- Merck & Co., Inc. MRK 146.65 −0.20%
Gilead Sciences, Inc. and Merck & Co., Inc. are both Drug Manufacturers General companies. Merck & Co., Inc. is the larger, with a market value of $362.5B against $207.8B — 1.7× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Merck & Co., Inc. trades at 118×. Gilead Sciences, Inc. grew revenue faster over the last twelve months: 6.54% against 4.89%. Merck & Co., Inc. has the higher net margin (3.64% vs −12.5%) and the higher return on invested capital (0.00% vs −4.51%). Both pay a dividend; Merck & Co., Inc. yields more (2.31% vs 1.94%). Across the 22 metrics below, Merck & Co., Inc. leads on 14 and Gilead Sciences, Inc. on 8.
Valuation
Profitability
| Metric | GILD | MRK | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 79.93% | 71.75% | 73.01% |
| Operating margin | (7.63%) | 9.20% | 18.34% |
| Net margin | (12.47%) | 3.64% | 7.31% |
| Free cash flow margin | 44.47% | 0.00% | 18.52% |
| Return on equity | (22.45%) | 0.00% | 5.80% |
| Return on assets | (7.03%) | 0.00% | 2.28% |
| Return on invested capital | (4.51%) | 0.00% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack